EGFR and glioblastoma: While activation of compensatory oncogenic signalling pathways such as the PI3K and MET pathways contributes to resistance against EGFR inhibitors in GBM, a significant limitation in current EGFR inhibitors is the specificity of its mechanism of action [49].